Elanco Animal Health stock is trading -7.68% below its average target price of $19.53 after marking a 1.6% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $16.0 to $23.0 per share.
The stock has an average amount of shares sold short at 5.5%, and a short ratio of 3.37. Only 0.66% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.3% of Elanco Animal Health's shares being owned by this investor type.
Institutions Invested in Elanco Animal Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Dodge & Cox Inc | 17% | 83,848,850 | $1,511,794,823 |
| 2024-03-31 | Primecap Management Company | 11% | 52,885,068 | $953,517,812 |
| 2024-03-31 | Vanguard Group Inc | 10% | 49,258,240 | $888,126,101 |
| 2024-03-31 | Blackrock Inc. | 5% | 26,639,783 | $480,315,305 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 4% | 22,139,018 | $399,166,509 |
| 2024-03-31 | Black Creek Investment Management Inc. | 4% | 20,159,435 | $363,474,626 |
| 2024-03-31 | Dimensional Fund Advisors LP | 4% | 17,995,962 | $324,467,207 |
| 2024-03-31 | Citadel Advisors Llc | 2% | 12,081,728 | $217,833,564 |
| 2024-03-31 | Shapiro Capital Management Company, Inc. | 2% | 10,893,298 | $196,406,170 |
| 2024-03-31 | Ancora Advisors, LLC | 2% | 10,641,194 | $191,860,735 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Elanco Animal Health.
